“There is nothing more important than giving the gift of sight to my patients. Additional vision, and the opportunity to see 20/40 or better, means they can take care of themselves, live more independently, enjoy life, and do what they love. It also means they have a lower risk of falling and being injured, they stay socially connected, and maintain their mental health. Every letter counts when it comes to improving vision.”
Every letter counts when it comes to improving vision
The Unmet Need of Achieving Superior Visual Outcomes
Why Retinal Diseases Can Lead to Permanent Vision Loss.
Retinal diseases such as wet AMD and DME share the same pathology where excessive presence of members of the VEGF family lead to vision decline. Current treatments are primarily inhibiting VEGF-A, a prominent member of the VEGF family. Research has shown that when VEGF-A is inhibited, levels of other members of the VEGF family, like VEGF-C and VEGF-D, are elevated, which may lead to suboptimal vision outcomes.
The VEGF family are proteins produced by cells that stimulate the formation of new abnormal blood vessels, a process called angiogenesis, and induces vascular permeability, leading to leakage and swelling of the retina. Swelling of the retina leads to vision decline and death of the retinal cells, which can irreversibly cause blindness if not adequately treated.
The Majority of Patients with Wet AMD Fail to Achieve 20/40 Vision, Despite Sustained Treatment with Anti-VEGF-A Therapy
When the first anti-VEGF-A treatment became available 20 years ago, patients with wet AMD had a transformational experience – they went from fear of going blind to confidence in being able to see. However, randomized clinical trial data and real-world evidence show that despite treatment with standard-of-care anti-VEGF-A therapies, the majority of patients with wet AMD only achieve suboptimal vision outcomes.
Transforming Patient Outcomes
Sozinibercept Phase 2b Data Show Substantial Vision Gains
In a large prospective, randomized, and controlled Phase 2b clinical trial of 366 treatment-naïve wet AMD patients, a greater proportion of patients treated with sozinibercept, a novel, first-in-class VEGF-C/D ‘trap’ inhibitor, in combination with standard-of-care anti-VEGF-A therapy, achieved clinically significant vision gains and fewer experienced vision loss compared to standard of care.
Change from Baseline to Week 24 (ETDRS Letters, Individual Participants)
Occult and Minimally Classic Lesions (RAP Absent)
Sozinibercept is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST and ShORe) designed to assess the safety and superior efficacy of sozinibercept combination therapy versus standard-of-care anti-VEGF-A therapies for the treatment of wet AMD.
Connecting to Helpful Resources
People with vision-threatening diseases such as wet AMD are not alone. Get connected, learn about living with vision impairment and therapies that may help you live a fuller and healthier life.
Patient groups you may find helpful: